Copy-number dosage regulates telomere maintenance and disease-associated pathways in neuroblastoma
Martin BurkertiD, Eric BlanciD, Nina Thiessen, Christiane Weber, Joern ToedlingiD, Remo MontiiD, Victoria M DombroweiD, Maria Stella de BiaseiD, Tom L. KaufmanniD, Kerstin HaaseiD, Sebastian M. WaszakiD, Angelika EggertiD, Dieter BeuleiD, Johannes Hubertus SchulteiD, Uwe OhleriD, Roland F. SchwarziD
Abstract
Telomere maintenance in neuroblastoma is linked to poor outcome and caused by either TERT activation or through alternative lengthening of telomeres (ALT). In contrast to TERT activation, commonly caused by genomic rearrangements or MYCN amplification, ALT is less well understood. Alterations at the ATRX locus are key drivers of ALT but only present in [~]50% of ALT tumors. To identify potential new pathways to telomere maintenance, we investigate allele-specific gene dosage effects from whole genomes and transcriptomes in 115 primary neuroblastomas. We show that copy-number dosage deregulates telomere maintenance, genomic stability, and neuronal pathways and identify upregulation of variants of histone H3 and H2A as a potential alternative pathway to ALT. We investigate the interplay between TERT activation, overexpression and copy-number dosage and reveal loss of imprinting at the RTL1 gene associated with poor clinical outcome. These results highlight the importance of gene dosage in key oncogenic mechanisms in neuroblastoma.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 0.00
- Field percentile
- 20th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ALT Neuroblastoma Chemoresistance due to ATM Activation by Telomere Dysfunction is Reversible with the ATM Inhibitor AZD0156
B. Koneru, A. Farooqi, … C. P. Reynolds·bioRxiv·Apr 6, 2021
- The TERT promoter is polycomb-repressed in neuroblastoma cells with long telomeres
M. K. Graham, B. Xu, … M. Zeineldin·bioRxiv·May 18, 2022
- METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma
R. Vaid, K. Thombare, … T. Mondal·Nucleic Acids ResearchPeer-reviewed·Mar 21, 2024
- Expression of telomerase prevents ALT and maintains telomeric heterochromatin in juvenile brain tumors.
A. I. Idilli, E. Cusanelli, … M. C. Mione·bioRxiv·Jul 30, 2019
- Reciprocal impacts of telomerase activity and tumor cell differentiation in neuroblastoma tumor biology
E. Y. Yu, S. S. Zahid, … N. Lue·bioRxiv·May 9, 2021
- SLFN11 puts the brakes on Alternative lengthening of telomeres
Prashant Khandagale, Allison L Welter, … Yves G. Pommier·bioRxiv·Dec 11, 2025